相关实验视频
Updated: Mar 17, 2026

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.3K
精准医学时代的心力衰竭:进展,挑战和未来方向
1Internal Medicine Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain.
Current cardiology reviews
|March 15, 2026
概括
最近心力衰竭 (HF) 管理方面的进展包括-葡萄糖共传输体-2 抑制剂 (SGLT2i) 和精密医学. 解决接入差异和实施障碍对于改善各种高频群体的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 心脏衰竭 (HF) 是一个主要的全球健康挑战,具有不同的临床表现.
- 在管理HF时,个性化护理越来越重要.
- 药物治疗,设备干预和精准医学正在改变HF治疗.
研究的目的:
- 审查心力衰竭 (HF) 管理的最新发展.
- 识别HF护理中持续存在的挑战和新出现的机会.
- 综合临床试验和指南更新的证据.
主要方法:
- 对2020年1月至2024年12月发表的研究进行了叙述性审查.
- 搜索了包括PubMed/MEDLINE,Scopus和Web of Science在内的主要数据库.
- 根据临床相关性,证据稳定性和适用性进行选择的研究.
主要成果:
- -葡萄糖共载体-2 抑制剂 (SGLT2i) 在整个射出分数谱中有效.
- 像 vericiguat 和 omecamtiv mecarbil 这样的新疗法解决了尚未满足的需求.
- 精准医学,包括基因测试和生物标志物,对量身定制的高频率干预有希望.
- 在获取和试验代表人数不足方面的差异仍然是重大挑战.
结论:
- 新型药物和精准医学已经扩大了HF的治疗选择.
- 公平的获取,新技术的验证和现实世界的实施是关键的挑战.
- 多学科护理和实用性试验对于提高HF患者的治疗结果至关重要.
相关概念视频
Heart Failure V: Medical Management
470
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
470
Cardiomyopathy V: Interprofessional Care
584
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584
Cardiomyopathy II: Dilated Cardiomyopathy
716
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
Pathophysiology of Heart Failure
4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
618
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
618
Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
